Human CD3-specific antibody with immunosuppressive properties
Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.
1. A method for immunotherapy comprising the step of administering to a subject a pharmaceutical composition comprising
(i) a bivalent diabody comprising a non-covalent dimer of single-chain Fv-antibodies each consisting essentially of a V H domain and a V L domain specific to human CD3, wherein the V H domain and the V L domain are covalently linked either without a linker or with a peptide linker, the bivalent diabody is characterized by the following features:
(a) it is devoid of constant antibody domains;
(b) it specifically binds to an epitope of human TCR/CD3 complex bivalently; and
(c) it is capable of suppressing an immune reaction; and
(ii) a suitable pharmaceutical carrier, wherein said immunotherapy is a therapy against acute transplant rejections, type I diabetes, multiple sclerosis or rheumatoid arthritis.
2. A method for immunotherapy comprising the step of administering to a subject a pharmaceutical composition comprising
(i) a non-covalent dimer of single-chain Fv-antibodies (scFvs), each scFv with one V H domain and one V L domain specific to human CD3, wherein each V H -V L pair is separated by a peptide linker or bound by a peptide bond, the non-covalent dimer of single-chain F v -antibodies characterized by the following features:
(a) it is devoid of constant antibody domains;
(b) it specifically binds to an epitope of human TCR/CD3 complex bivalently;
(c) it is capable of suppressing an immune reaction; and
(ii) a suitable pharmaceutical carrier, wherein said immunotherapy is a therapy against acute transplant rejections, type I diabetes, multiple sclerosis or rheumatoid arthritis.
3. The method according to claim 1 or 2 , wherein the suitable pharmaceutical carrier is selected from the group consisting of an emulsion, a wetting agent and a sterile solution.
4. The method according to claim 1 or 2 , wherein said immunotherapy is a therapy against acute transplant rejections.
5. The method according to claim 1 or 2 , wherein the V H domain and the V L domain of the bivalent diabody are covalently linked via a peptide linker SAKTTP (SEQ ID NO:1).
6. The method according to claim 1 or 2 , wherein the V H domain and the V L domain of the bivalent diabody correspond to the variable domains of an antibody produced by the hybridoma of ATCC deposit number CRL 8001.